

U.S.S.N. 08/823,999  
Filed: March 25, 1997  
AMENDMENT

#### Claims Listing

1. (Currently amended) A method of inhibiting or reducing stenosis arising from coronary artery bypass surgery, peripheral bypass surgery, or transplantation of cells, tissue or organs or restenosis of a blood vessel following injury to vascular tissue in a region of the blood vessel of a patient in need of treatment thereof, comprising:

administering systemically or at the site of the injury a pharmaceutically acceptable composition comprising a compound which specifically inhibits or reduces leukocyte integrin-mediated adhesion or function,

wherein the integrin is selected from the group consisting of Mac-1 (CD11b/CD18), LFA-1 (CD11a/CD18), p150,95 (CD11c/CD18), and CD11d/CD18,

wherein the compound is selected from the group consisting of antibodies and antibody fragments that are immunoreactive with the integrins or their integrin-ligands and which block the interaction of the the integrins or their integrin-ligands with vascular cells; molecules which inhibit expression of the integrins or their integrin-ligands, and peptides and peptidomimetics derived from the integrins or their integrin-ligands which block the interaction of the integrins or their integrin-ligands with vascular cells or tissues,

in an amount effective to inhibit or reduce stenosis arising from coronary artery bypass surgery, peripheral bypass surgery, or transplantation of cells, tissue or organs or dependent restenosis of a blood vessel following injury to vascular tissue.

U.S.S.N. 08/823,999

Filed: March 25, 1997

AMENDMENT

2. (Original) The method of claim 1 wherein the leukocytes are monocytes or granulocytes.

3. (currently amended) The method of claim 1 wherein the injury arises from angioplasty, atherectomy, or endovascular stenting, ~~coronary artery bypass surgery, peripheral bypass surgery, or transplantation of cells, tissue or organs.~~

4. (Original) The method of claim 1 wherein the composition is in a form selected from the group consisting of solutions, gels, foams, suspensions, polymeric carriers, and liposomes.

5. (Previously presented) The method of claim 1 wherein the integrin is selected from the group consisting of LFA-1 (CD11a/CD18), p150,95 (CD11c/CD18), and CD11d/CD18.

6. (Currently amended) ~~The method of claim 5~~ A method of inhibiting or reducing stenosis arising from coronary artery bypass surgery, peripheral bypass surgery, or transplantation of cells, tissue or organs or restenosis of a blood vessel following injury to vascular tissue in a region of the blood vessel of a patient in need of treatment thereof, comprising:

administering systemically or at the site of the injury a pharmaceutically acceptable composition comprising a compound which specifically inhibits or reduces leukocyte integrin-mediated adhesion or function,

U.S.S.N. 08/823,999  
Filed: March 25, 1997  
AMENDMENT

wherein the integrin is selected from the group consisting of Mac-1 (CD11b/CD18),  
~~LFA-1 (CD11a/CD18), p150,95 (CD11c/CD18), and CD11d/CD18,~~

wherein the compound is selected from the group consisting of antibodies and antibody fragments that are immunoreactive with the integrins or integrin-ligands and which block the interaction of the integrins or integrin-ligands with vascular cells; molecules which inhibit expression of the integrins or integrin-ligands, and peptides and peptidomimetics derived from the integrins or integrin-ligands which block the interaction of the integrins or integrin-ligands with vascular cells or tissues,

in an amount effective to inhibit or reduce stenosis arising from coronary artery bypass surgery, peripheral bypass surgery, or transplantation of cells, tissue or organs or restenosis of a blood vessel following injury to vascular tissue.

wherein the integrin is Mac-1 (CD11b/CD18).

7. (Withdrawn) The method of claim 6 5 wherein the ligand is selected from the group consisting of ICAM-1, fibrin(ogen), C3bi, and factor X.

8. (Previously presented) The method of claim 1 wherein the compound is selected from the group consisting of antibodies and antibody fragments that are immunoreactive with the integrins or their ligands and which block the interaction of the integrins or their ligands with vascular cells.

9. (Withdrawn) The method of claim 5 wherein the integrin is LFA-1 and the ligand is selected from the group consisting of ICAM-1, ICAM-2, ICAM-3.